• Silymarin: Chemistry, Evidence, and Limits

  2026-10-13

  The supplied evidence supports a chemistry-centered interpretation of Silymarin and cautions against treating a heterogeneous milk thistle extract as equivalent to purified silybin or as proof of clinical efficacy.

• PTGER4–HDAC Signaling in Rectal Epithelium

  2026-10-13

  Anbazhagan et al. report that MSC-associated PGE2 signaling through PTGER4 is linked to class IIa HDAC phosphorylation and increased SPINK4 expression in rectal epithelial organoids. The findings support a mechanistic model, but the evidence remains primarily ex vivo and pharmacological rather than proof of in vivo causation or therapeutic benefit.

• SIRT1, Bone Aging, and EX 527 Evidence

  2026-10-12

  A source-grounded overview of SIRT1 in vascular–osteogenic bone repair, the reported role of β-catenin signaling, and the interpretive scope of EX 527 (SEN0014196) as a selective SIRT1 catalytic-activity inhibitor.

• AZD8055: Documented Identity and Evidence Scope

  2026-10-12

  AZD8055 is listed by APExBIO as a selective ATP-competitive mTOR inhibitor intended as a research tool for conceptual study of mTORC1 and mTORC2 signaling. The available evidence here is limited to a supplier description, so its reported potency, selectivity, preclinical activity, and clinical history cannot be independently assessed.

• Losmapimod and p38α Dephosphorylation

  2026-10-11

  A source-grounded overview of a 2024 bioRxiv preprint examining how kinase-inhibitor binding changes p38α activation-loop conformation and WIP1-mediated dephosphorylation. The findings support a preliminary mechanistic model, but the supplied evidence does not establish that Losmapimod or GW856553X was tested, nor that the mechanism operates in cells or patients.

• BAPTA-AM: Product Identity and Research Scope

  2026-10-10

  BAPTA-AM (SKU B4758; CAS 126150-97-8) is listed by APExBIO as a cell-permeable calcium chelator. No matched paper evidence was provided, so this overview is limited to documented identity and conceptual scope.

• HyperScribe mRNA Kit: Evidence and Research Context

  2026-10-09

  The HyperScribe All in One mRNA Synthesis Kit Plus 1 is presented by APExBIO as an ARCA-capped, modified and polyadenylated mRNA synthesis platform. This overview separates supplier-described features from peer-reviewed evidence, using a 2025 murine cryptococcosis study to assess what can—and cannot—be inferred about RNA vaccine development, modified mRNA translation and immune response reduction.

• Cyclosporin A: Mechanisms, Mitochondria and Evidence

  2026-10-09

  Cyclosporin A is best understood as a mechanistically versatile cyclic undecapeptide whose immunosuppressive and mitochondrial effects should not be treated as interchangeable. This overview examines the structural and functional evidence from a 2020 comparison of cyclosporin variants, explains what the findings suggest about mitochondrial permeability transition pore inhibition, and outlines the study’s limitations for T-cell, transplantation, autoimmune disease, and broader biomedical research.

• UBR1 and UBR2 as Mammalian ER Stress Sensors

  2026-10-08

  The reference study identifies the N-recognin E3 ligases UBR1 and UBR2 as previously underappreciated components of mammalian endoplasmic reticulum quality control. Its findings connect stress-dependent stabilization of these proteins with protection from apoptosis, expanding current models of ER-associated degradation beyond canonical membrane-embedded ligases.

• BMX–ATP6V1E1 Signaling in Mtb Survival

  2026-10-08

  A 2026 Nature Communications study reports that Mycobacterium tuberculosis secretes Chp2/Rv1184 to promote BMX-dependent phosphorylation of the V-ATPase subunit ATP6V1E1, weakening lysosomal acidification and supporting intracellular survival. The findings identify a host–pathogen signaling axis relevant to host-directed tuberculosis research while leaving questions about human translation, selectivity, and therapeutic safety unresolved.

• SN-38, FUBP1, and FUSE: What the Study Shows

  2026-10-07

  A 2017 Biochemical Pharmacology study identified camptothecin and SN-38 as inhibitors of the interaction between the transcriptional regulator FUBP1 and its single-stranded DNA target, FUSE. The findings extend the mechanistic interpretation of topoisomerase I drugs by linking their activity to transcriptional regulation, while remaining limited to biochemical screening and cell-based evidence.

• ML385 and NRF2: Reading Ferroptosis Evidence

  2026-10-07

  ML385 is an NRF2 inhibitor that can help researchers test whether antioxidant signaling contributes to ferroptosis and alcoholic liver injury. This evidence-focused guide explains what the Poria cocos study shows, what it does not prove, and how the compound supports stronger mechanistic interpretation.

• How Mtb Uses BMX to Control Lysosomal Acidification

  2026-10-06

  A 2026 Nature Communications study identifies a host–pathogen mechanism in which Mycobacterium tuberculosis uses the secreted protein Chp2 to promote BMX-dependent phosphorylation of ATP6V1E1, weakening V-ATPase assembly and lysosomal acidification. The findings connect host kinase signaling to phagosome maturation and support further investigation of BMX as a possible host-directed therapeutic target, while remaining subject to model-specific and translational limitations.

• Brassinolide: Research Context and Evidence

  2026-10-06

  Brassinolide is a plant brassinosteroid studied as a growth-regulating hormone and as a reference compound for structure–activity research. This overview compares findings from rice and bean bioassays, explains what supplier-reported cancer and diabetes results can—and cannot—establish, and defines important evidence and applicability limits.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-10-05

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that connects ENO1 acetylation and lactate production with TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated patient, multi-omics, cellular, and mouse-model evidence suggests that the NAT1–ENO1–lactate axis may influence responses to immune checkpoint blockade, while remaining preclinical.

8235 records 3/549 page Previous Next 12345 下5页 Last page